> 90% diagnostic accuracy
~ 70% reduction in indeterminate diagnoses
> 80% reduction of overtreatment in myPath Benign cases
Fact Sheets and Product Info:
Find more Myriad info as well as links to National Institutes of Health melanoma resources.
Melanoma is an aggressive cancer with an estimated 96,480 cases and 7,320 deaths in 2019. The lifetime risk of developing melanoma in the United States is 1 in 34 for men and 1 in 54 for women.
However, many melanomas are curable if they are detected early and diagnosed accurately. The 10-year survival rate for patients with stage I melanomas is 86-95%, compared with only 10-15% among patients with stage IV melanomas.
About myPath Melanoma:
myPath Melanoma may be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate/ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.